MX366405B - Uso de peptidos glp-1 de accion prolongada. - Google Patents

Uso de peptidos glp-1 de accion prolongada.

Info

Publication number
MX366405B
MX366405B MX2014014946A MX2014014946A MX366405B MX 366405 B MX366405 B MX 366405B MX 2014014946 A MX2014014946 A MX 2014014946A MX 2014014946 A MX2014014946 A MX 2014014946A MX 366405 B MX366405 B MX 366405B
Authority
MX
Mexico
Prior art keywords
peptides
long
acting glp
glp
acting
Prior art date
Application number
MX2014014946A
Other languages
English (en)
Other versions
MX2014014946A (es
Inventor
Bjørn Jensen Christine
Frederik Rasmussen Mads
Zdravkovic Milan
Kristensen Peter
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49881374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366405(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2014014946A publication Critical patent/MX2014014946A/es
Publication of MX366405B publication Critical patent/MX366405B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

La presente invención se refiere a uso de péptidos GLP-1 de acción prolongada en ciertos regímenes de dosificación para el tratamiento de diabetes tipo 2, obesidad, etc.
MX2014014946A 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada. MX366405B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781 2012-10-01
PCT/EP2013/063004 WO2014005858A1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides

Publications (2)

Publication Number Publication Date
MX2014014946A MX2014014946A (es) 2015-04-08
MX366405B true MX366405B (es) 2019-07-08

Family

ID=49881374

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014014946A MX366405B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.
MX2020010693A MX2020010693A (es) 2012-07-01 2014-12-05 Uso de peptidos glp-1 de accion prolongada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010693A MX2020010693A (es) 2012-07-01 2014-12-05 Uso de peptidos glp-1 de accion prolongada.

Country Status (11)

Country Link
US (2) US9764003B2 (es)
EP (2) EP3689365A1 (es)
JP (1) JP6059802B2 (es)
AU (3) AU2013286177B2 (es)
BR (1) BR112014032938A2 (es)
CA (1) CA2877056A1 (es)
MX (2) MX366405B (es)
RS (1) RS60432B1 (es)
RU (1) RU2657573C2 (es)
SI (1) SI2866825T1 (es)
WO (1) WO2014005858A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013014942B1 (pt) 2010-12-16 2020-01-28 Novo Nordisk As composições sólidas para administração, e seus usos
ES2612278T3 (es) 2011-04-12 2017-05-16 Novo Nordisk A/S Derivados de GLP-1 doble-acilados
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
AU2013286177B2 (en) 2012-07-01 2018-04-26 Novo Nordisk A/S Use of long-acting GLP-1 peptides
KR102127624B1 (ko) * 2014-10-16 2020-06-29 얀마 파워 테크놀로지 가부시키가이샤 작업 차량
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
PE20211202A1 (es) 2017-08-24 2021-07-05 Novo Nordisk As Composiciones de glp-1 y sus usos
WO2019072941A1 (en) * 2017-10-12 2019-04-18 Novo Nordisk A/S SEMAGLUTIDE IN MEDICAL THERAPY
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
WO2020028907A1 (en) * 2018-08-03 2020-02-06 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
WO2021089678A1 (en) * 2019-11-06 2021-05-14 Novo Nordisk A/S Glp-1 receptor agonists in dementia
PE20221575A1 (es) * 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
EP4359074A2 (en) * 2021-06-24 2024-05-01 Gila Therapeutics, Inc. Methods and kits for inducing satiety and treating metabolic disorders
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CN114621339B (zh) * 2021-12-28 2022-09-23 北京惠之衡生物科技有限公司 一种长效glp-1衍生物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
EP2932981B1 (en) 2003-09-19 2021-06-16 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
JP5175103B2 (ja) * 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス 安定なペプチド製剤
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
MX2008013216A (es) * 2006-04-14 2008-10-27 Mannkind Corp Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1).
US20100047762A1 (en) 2007-03-20 2010-02-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
EP2679597A1 (en) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
PL2373681T3 (pl) 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu
EA029759B1 (ru) * 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
CA2784757A1 (en) * 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
AU2011249722B2 (en) * 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
BR112013014942B1 (pt) 2010-12-16 2020-01-28 Novo Nordisk As composições sólidas para administração, e seus usos
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
US20140220134A1 (en) * 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
AU2013286177B2 (en) 2012-07-01 2018-04-26 Novo Nordisk A/S Use of long-acting GLP-1 peptides

Also Published As

Publication number Publication date
SI2866825T1 (sl) 2020-07-31
JP6059802B2 (ja) 2017-01-11
AU2020202573B2 (en) 2023-04-20
AU2018202504A1 (en) 2018-05-10
US10335462B2 (en) 2019-07-02
RU2015101826A (ru) 2016-08-20
JP2015522573A (ja) 2015-08-06
RS60432B1 (sr) 2020-07-31
AU2013286177B2 (en) 2018-04-26
AU2013286177A1 (en) 2015-01-15
US9764003B2 (en) 2017-09-19
CA2877056A1 (en) 2014-01-09
MX2020010693A (es) 2020-11-06
EP2866825A1 (en) 2015-05-06
BR112014032938A2 (pt) 2017-08-01
EP3689365A1 (en) 2020-08-05
EP2866825B1 (en) 2020-04-08
WO2014005858A1 (en) 2014-01-09
MX2014014946A (es) 2015-04-08
US20150190474A1 (en) 2015-07-09
RU2657573C2 (ru) 2018-06-14
US20180085435A1 (en) 2018-03-29
AU2018202504B2 (en) 2020-05-07
AU2020202573A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
MX2020010693A (es) Uso de peptidos glp-1 de accion prolongada.
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX2014015423A (es) Analogos de peptido de exedina-4.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2014002159A (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
IN2014CN02616A (es)
MX2015008114A (es) Derivados de exendina-4.
PH12015500115A1 (en) Glucagon analogues
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
MX2013015176A (es) Co-agonistas del receptor de glucagon/glp-1.
MX2020010991A (es) Composicion para la estimulacion ovarica controlada.
MX2021006111A (es) Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
MX2014005351A (es) Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
MX2016001691A (es) Moleculas de union al receptor bag3 para uso como un medicamento.
NZ703573A (en) Feijoa fruit extract
PH12017500923A1 (en) New dosage and use of a a2a antagonist
MX2019008148A (es) Uso de peptidos glp-1 de accion prolongada.
AU2012240388A8 (en) Treatment regimens
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
TN2013000524A1 (en) Glucagon/glp-1 receptor co-agonists
UA97054C2 (ru) Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ

Legal Events

Date Code Title Description
FG Grant or registration